Sprint Bioscience AB (SPRINT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.182x

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has a cash flow conversion efficiency ratio of -0.182x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-19.29 Million ≈ $-2.08 Million USD) by net assets (Skr106.29 Million ≈ $11.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SPRINT net asset quality score to measure how much of total assets are equity-financed.

Sprint Bioscience AB - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Sprint Bioscience AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sprint Bioscience AB (SPRINT) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Sprint Bioscience AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sprint Bioscience AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Wisher Industrial Co Ltd TW:1465	-0.178x
Casing Macron Technology Co Ltd TWO:3325	0.026x
AbL Diagnostics SA PA:ABLD	0.063x
WT Financial Group Ltd AU:WTL	0.125x
Zegona Communications Plc LSE:ZEG	0.120x
Rodex Fasteners TWO:5015	0.010x
RAIZ Invest Ltd AU:RZI	0.054x
Firetail Resources Ltd AU:FTL	-0.038x

Annual Cash Flow Conversion Efficiency for Sprint Bioscience AB (2012–2025)

The table below shows the annual cash flow conversion efficiency of Sprint Bioscience AB from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Sprint Bioscience AB.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr119.18 Million ≈ $12.83 Million	Skr83.53 Million ≈ $8.99 Million	0.701x	+127.83%
2024-12-31	Skr9.27 Million ≈ $997.82K	Skr-23.36 Million ≈ $-2.51 Million	-2.519x	-405.90%
2023-12-31	Skr27.77 Million ≈ $2.99 Million	Skr22.87 Million ≈ $2.46 Million	0.823x	+139.31%
2022-12-31	Skr28.19 Million ≈ $3.03 Million	Skr-59.05 Million ≈ $-6.36 Million	-2.095x	-267.93%
2021-12-31	Skr70.45 Million ≈ $7.58 Million	Skr-40.12 Million ≈ $-4.32 Million	-0.569x	+83.84%
2020-12-31	Skr9.14 Million ≈ $984.04K	Skr-32.22 Million ≈ $-3.47 Million	-3.524x	-38.64%
2019-12-31	Skr11.02 Million ≈ $1.19 Million	Skr-28.00 Million ≈ $-3.01 Million	-2.542x	-396.07%
2018-12-31	Skr37.24 Million ≈ $4.01 Million	Skr-19.08 Million ≈ $-2.05 Million	-0.512x	+37.56%
2017-12-31	Skr28.09 Million ≈ $3.02 Million	Skr-23.05 Million ≈ $-2.48 Million	-0.821x	-394.71%
2016-12-31	Skr28.49 Million ≈ $3.07 Million	Skr7.93 Million ≈ $853.92K	0.278x	+61.03%
2015-12-31	Skr4.82 Million ≈ $518.74K	Skr833.54K ≈ $89.70K	0.173x	+132.66%
2014-12-31	Skr20.32 Million ≈ $2.19 Million	Skr-10.76 Million ≈ $-1.16 Million	-0.529x	+50.07%
2013-12-31	Skr3.36 Million ≈ $361.91K	Skr-3.57 Million ≈ $-383.76K	-1.060x	+49.25%
2012-12-31	Skr1.10 Million ≈ $118.06K	Skr-2.29 Million ≈ $-246.66K	-2.089x	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$41.11 Million

Skr381.97 Million SEK

Market Cap Rank

#22598 Global

#431 in Sweden

Share Price

Skr3.62

Change (1 day)

+0.56%

52-Week Range

Skr0.56 - Skr4.49

All Time High

Skr47.75